Peter Van den Steen

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 14

Top Venues

Human vaccines & immunotherapeutics

COPD

GSK Vaccines

This page only lists publications with an associated author ORCID identifier.

Affiliation History

GSK Vaccines Apr 01 2015

Belgium

Clinical Research and Development Lead :: Clinical development

Publications

Federico M Torres, Ignacio Salamanca de la Cueva, Michael Horn, Soeren Westerholt, Samantha Bosis, Nadia Meyer, Brigitte Cheuvart, Navpreet Virk, Rupert W Jakes, Maurine Duchenne, Peter Van den Steen
Disparate kinetics in immune response of two different Haemophilus influenzae type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule. Human vaccines & immunotherapeutics 20 (1) (2024)
Federico M Torres, Ignacio Salamanca de la Cueva, Michael Horn, Soeren Westerholt, Samantha Bosis, Nadia Meyer, Brigitte Cheuvart, Navpreet Virk, Rupert W Jakes, Maurine Duchenne, Peter Van den Steen
Disparate kinetics in immune response of two different Haemophilus influenzae type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule. Human vaccines & immunotherapeutics 20 (1) (2024)
Federico M Torres, Ignacio Salamanca de la Cueva, Michael Horn, Soeren Westerholt, Samantha Bosis, Nadia Meyer, Brigitte Cheuvart, Navpreet Virk, Rupert W Jakes, Maurine Duchenne, Peter Van den Steen
Disparate kinetics in immune response of two different Haemophilus influenzae type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule. Human vaccines & immunotherapeutics 20 (1) (2024)
Federico M Torres, Ignacio Salamanca de la Cueva, Michael Horn, Soeren Westerholt, Samantha Bosis, Nadia Meyer, Brigitte Cheuvart, Navpreet Virk, Rupert W Jakes, Maurine Duchenne, Peter Van den Steen
Disparate kinetics in immune response of two different Haemophilus influenzae type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule. Human vaccines & immunotherapeutics 20 (1) (2024)
Peter Van den Steen, Brigitte Cheuvart, Quentin Deraedt, Laura Valdes Verelst, Daria Shamarina
Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases. Human vaccines & immunotherapeutics 19 (1) (2023)
Peter Van den Steen, Brigitte Cheuvart, Quentin Deraedt, Laura Valdes Verelst, Daria Shamarina
Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases. Human vaccines & immunotherapeutics 19 (1) (2023)
Peter Van den Steen, Brigitte Cheuvart, Quentin Deraedt, Laura Valdes Verelst, Daria Shamarina
Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases. Human vaccines & immunotherapeutics 19 (1) (2023)
Peter Van den Steen, Brigitte Cheuvart, Quentin Deraedt, Laura Valdes Verelst, Daria Shamarina
Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases. Human vaccines & immunotherapeutics 19 (1) (2023)
Peter Van den Steen, Brigitte Cheuvart, Quentin Deraedt, Laura Valdes Verelst, Daria Shamarina
Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases. Human vaccines & immunotherapeutics 19 (1) (2023)
Peter Van den Steen, Brigitte Cheuvart, Quentin Deraedt, Laura Valdes Verelst, Daria Shamarina
Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases. Human vaccines & immunotherapeutics (2023)
Peter Van den Steen, Brigitte Cheuvart, Quentin Deraedt, Laura Valdes Verelst, Daria Shamarina
Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases. Human vaccines & immunotherapeutics 19 (1) (2023)
Thomas M A Wilkinson, Peter Van den Steen, Brigitte Cheuvart, Nathalie Baudson, Monique Dodet, Elisa Turriani, Lauriane Harrington, Nadia Meyer, Simona Rondini, Laura Taddei, Piyali Mukherjee
Seroprevalence of Bordetella pertussis Infection in Patients With Chronic Obstructive Pulmonary Disease in England: Analysis of the AERIS Cohort. COPD 18 (3) (2021)
Asmik Asatryan, Nadia Meyer, Mikhail Scherbakov, Victor Romanenko, Irina Osipova, Anna Galustyan, Olga Shamsheva, Tatiana Latysheva, Tatyana Myasnikova, Nathalie Baudson, Monique Dodet, Stebin Xavier, Lauriane Harrington, Anastasia Kuznetsova, Laura Campora, Peter Van den Steen
Immunogenicity, safety, and reactogenicity of combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as a booster vaccine dose in healthy Russian participants: a phase III, open-label study. Human vaccines & immunotherapeutics 17 (3) (2020)
Lidia Oostvogels, Thomas C Heineman, Robert W Johnson, Myron J Levin, Janet E McElhaney, Peter Van den Steen, Toufik Zahaf, Alemnew F Dagnew, Roman Chlibek, Javier Diez-Domingo, Iris S Gorfinkel, Caroline Hervé, Shinn-Jang Hwang, Hideyuki Ikematsu, George Kalema, Himal Lal, Shelly A McNeil, Tomas Mrkvan, Karlis Pauksens, Jan Smetana, Daisuke Watanabe, Lily Yin Weckx, Anthony L Cunningham
Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. Human vaccines & immunotherapeutics 15 (12) (2019)

Peter Van den Steen.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Peter Van den Steen